BIOMARKER:

FGFR3 mutation

A1 | Sensitive

B | Sensitive

C1 | Sensitive

C2 | Sensitive

C3 | Sensitive

D | Sensitive

A1 | Resistant

B | Resistant

C1 | Resistant

C2 | Resistant

C3 | Resistant

D | Resistant

Urothelial Cancer

Melanoma

Solid Tumor

Bladder Cancer

Non Small Cell Lung Cancer

Cholangiocarcinoma

Breast Cancer

Gastric Cancer

Endometrial Cancer

erdafitinib

FGFR3 mutation|Urothelial Cancer|erdafitinib

FGFR3 mutation|Bladder Cancer|erdafitinib

FGFR3 mutation|Solid Tumor|erdafitinib

FGFR3 mutation|Cholangiocarcinoma|erdafitinib

FGFR3 mutation|Gastric Cancer|erdafitinib

infigratinib

FGFR3 mutation|Urothelial Cancer|infigratinib

FGFR3 mutation|Bladder Cancer|infigratinib

FGFR3 mutation|Breast Cancer|infigratinib

FGFR3 mutation|Endometrial Cancer|infigratinib

BAY 1163877

FGFR3 mutation|Urothelial Cancer|BAY 1163877

futibatinib

FGFR3 mutation|Urothelial Cancer|futibatinib

FGFR3 mutation|Solid Tumor|futibatinib

nintedanib

FGFR3 mutation|Non Small Cell Lung Cancer|nintedanib

pemigatinib

FGFR3 mutation|Urothelial Cancer|pemigatinib

B-701

FGFR3 mutation|Urothelial Cancer|B-701

enfortumab vedotin-ejfv

FGFR3 mutation|Urothelial Cancer|enfortumab vedotin-ejfv

CPL304110

FGFR3 mutation|Solid Tumor|CPL304110

dasatinib + infigratinib

FGFR3 mutation|Urothelial Cancer|dasatinib + infigratinib

PD-L1 inhibitor

FGFR3 mutation|Melanoma|PD-L1 inhibitor

CTLA4 inhibitor

FGFR3 mutation|Melanoma|CTLA4 inhibitor

Immunotherapy

FGFR3 mutation|Urothelial Cancer|Immunotherapy

FGFR3 mutation|Non Small Cell Lung Cancer|Immunotherapy

PD1 inhibitor

FGFR3 mutation|Melanoma|PD1 inhibitor